Grantham, Mayo, Van Otterloo & Co (GMO)’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-855	Closed	-$14K	–	786
2021 Q2	$14K	Hold	855	–	–	﹤0.01%	704
2021 Q1	$22K	Hold	855	–	–	﹤0.01%	831
2020 Q4	$31K	Hold	855	–	–	﹤0.01%	794
2020 Q3	$30K	Sell	855 -385	-31%	-$16.7K	﹤0.01%	757
2020 Q2	$53K	Buy	+1,240	New	+$83.6K	﹤0.01%	736

Other funds holding EVFM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s EVFM Position: Q3 2021 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2021, closing a stake of 855 shares — an estimated $14K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in EVFM in Q2 2020 and held it in 5 quarters. The position peaked at $53K in Q2 2020. 71 funds tracked by Wall St. Rank hold EVFM as of Q3 2021.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 855 Evofem Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $14K.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 5 quarters.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Evofem Biosciences, Inc. Common Stock position peaked at $53K in Q2 2020.
71 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2021.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2021, filed 12 Nov 2021.